Applied DNA Appoints New Head of Investor Relations and Corporate Communications
July 15 2020 - 7:00AM
Business Wire
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that enables in vitro diagnostics, and pre-clinical
nucleic acid-based therapeutic drug candidates, today announced the
appointment of Mr. Sanjay Hurry to Executive Director of Investor
Relations and Corporate Communications for the company. In this
role, Mr. Hurry will oversee the Company’s outreach with the
investment community and report to Dr. James A. Hayward, Chairman,
President, and Chief Executive Officer.
“We are thrilled to have Sanjay on board as we work to increase
and enhance our engagement with the investor community,” said Dr.
Hayward. “His demonstrated success in building strategic
communications programs that support business growth and deep
understanding of Applied DNA’s business will be key to helping us
broaden Wall Street’s awareness of our proprietary PCR-based linear
DNA manufacturing platform and its multiple applications across
industrial and therapeutic industries, the latter our emerging
diagnostics and vaccine development programs.”
Mr. Hurry brings over 20 years of investor relations and
corporate communications experience for public companies and with
investor relations agencies across a spectrum of diverse
industries. For the past five years he served as Vice President at
LHA Investor Relations, Applied DNA’s agency of record. He holds a
BA from New York University.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Applied DNA’s diagnostic candidates will
advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies, the unknown outcome of any applications or requests to
U.S. FDA, equivalent foreign regulatory agencies or New York State
Department of Health, the unknown limited duration of any Emergency
Use Authorization (EUA) approval from U.S. FDA, disruptions in the
supply of raw materials and supplies, and various other factors
detailed from time to time in Applied DNA’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
12, 2019 and our subsequent quarterly reports on Form 10-Q filed on
February 6, 2020 and May 14, 2020, and other reports we file with
the SEC, which are available at www.sec.gov. Applied DNA undertakes
no obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200715005139/en/
Investor contact: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024